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responsibility of XAbstract In this paper, we report the results of quality control based in physicochemical characteriza-
tion and impurities determination of three samples of ﬂuconazole drug substances marketed in Morocco.
These samples were supplied by different pharmaceuticals companies. The sample A, as the discovered
product, was supplied by Pﬁzer, while samples B and C (generics), were manufactured by two different
Indian industries. Solid-state characterization of the three samples was realized with different
physicochemical methods as: X-ray powder diffraction, Fourier-transformation infrared spectroscopy,
differential scanning calorimetry. High performance liquid chromatography was used to quantify the
impurities in the different samples. The results from the physicochemical methods cited above, showed
difference in polymorph structure of the three drug substances. Sample A consisted in pure polymorph
III, sample B consisted in pure polymorph II, sample C consisted in a mixture of ﬂuconazole Form III,
form II and the monohydrate. This result was conﬁrmed by differential scanning calorimetry. Also it was
demonstrated that solvents used during the re-crystallization step were among the origins of these
differences in the structure form. On the other hand, the result of the stability study under humidity and
temperature showed that ﬂuconazole polymorphic transformation could be owed to the no compliance
with the conditions of storage. The HPLC analysis of these compounds showed the presence of speciﬁcersity. Production and hosting by Elsevier B.V. All rights reserved.
.007
6 61450645;
.net.ma (A. Bouklouze).
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crystalline form of ﬂuconazole.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The polymorphism of drugs has been an important issue in the
pharmaceutical industry. Although identical in chemical com-
position, polymorphs differ in bioavailability, solubility,
dissolution rate, chemical stability, physical stability, melting
point, and many other properties. In particular, the variation
in solubility between different polymorphs can affect drug
efﬁcacy, bioavailability and safety [1–4].
Fluconazole (2,4-diﬂuoro-10,10-bis(1H-1,2,4-triazol-1-ylmethyl)
benzyl alcohol – C13H12F2N6O, 306.27 g/mol — is a triazole
antifungal agent with high oral efﬁciency. It was discovered in
1981, by a group of scientists in Pﬁzer Central Research in
Sandwich, Kent. This molecule is well tolerated, with no major
adverse reactions; it shows an optimum combination of antifungal
activity, pharmacokinetic proﬁle, and water solubility. Flucona-
zole is used against superﬁcial and systemic candidiasis and in the
treatment of cryptococcal infections for patients with the acquired
immunodeﬁciency syndrome [5–10].
This active pharmaceutical ingredient (API) crystallizes
in more than one solid form (polymorphs). First, two
polymorphic forms of ﬂuconazole were reported by Gu and
Jiang using FT-Raman and X-rays diffraction [11]. Dash [12]
and Alkhamis [13] reported that three polymorphs (form I, II
and III as designed by the authors) and a monohydrate form
have been distinguished by pﬁzer‘s scientists. Many solvates of
ﬂuconazole were reported in literature but without any
pharmaceutical interest [11–15].
The present study was conducted by the Moroccan
National Laboratory for the Control of Medicinal Products
(LNCM) in the context of a series of surveys of the quality of
the medicinal products marketed in Morocco with the aim of
comparing the quality of initially-discovered products and the
corresponding generics.
The ﬁrst part of this work focused on the physical aspect of the
purity issue (polymorphism, crystallinityy). All APIs were
analysed by X-ray diffraction (XRD), Fourier-transform infrared
spectroscopy (FTIR) and differential scanning calorimetry (DSC).
These methods put in evidence the differences between APIs.
The second one was on controlling the impurities in
ﬂuconazole API, through high performance liquid chromato-
graphy (HPLC), and demonstrating whether there is a rela-
tionship between the presence of speciﬁc impurities to each
APIs and its polymorphic form.
We highlighted the importance of solvents used in the
process of synthesis and puriﬁcation which could be at the
origin of these differences and determined the stability of each
crystalline form under the effect of temperature and humidity.2. Experimental
2.1. Chemicals
Sample A was supplied by Pﬁzer (Ireland). Samples B and C
were manufactured in India. All three samples consisted invery ﬁne white powder. The ﬂuconazole contents were 99.9,
99.6 and 100.3%, respectively.
The primary reference standard used was that of the US
Pharmacopoeia (Cat. No. 1271700).
Impurities reference standards [IMPI (i), IPMII (h), IMPIII
(a), IMPIV (g), and IMPV (f)] were provided by a pharma-
ceutical laboratory located in India.
The monohydrate was prepared by storing sample A under
controlled relative humidity and temperature conditions
(RH470%; 25 1C). All the samples were delivered in sealed
containers at room temperature and the various analyses were
conducted under controlled relative humidity and temperature
conditions.
2.2. Apparatus
2.2.1. Loss on drying
On drying the losses of the various ﬂuconazole samples were
determined as the United State Pharmacopoeia monograph on
ﬂuconazole (USP 29).
2.2.2. X-ray diffraction
The X-ray diffractograms of the powders were recorded
between 5 and 351 (2y), at room temperature, using a Philips
X’Pert-Pro spectrometer ﬁtted with an ultrafast detector
X’Celeratar and a copper anticathode (l¼1.5404 A˚, 45 kV,
40 mA). The diffractograms were recorded with a step width
of 0.0171(2y) and a count time of 11.16 s per step. The
mixtures were prepared by grinding together known quantities
of pure polymorphs III and II using agate pestle and mortar.
2.2.3. Fourier-transform infrared spectroscopy (FTIR)
The transmission FTIR spectra were recorded at room
temperature using a Bruker-Tensor 27 spectrometer. Each
spectrum was an average of 20 scans at 4 cm1 resolution over
the range 4000 to 400 cm1. Transparent, homogeneous disk
dilutions were prepared by grinding 1 to 3% of test product
with potassium bromide.
2.2.4. Differential scanning calorimetry (DSC)
The DSC thermograms of the ﬂuconazole samples were
recorded using differential scanning calorimeter DSC 2920
(TA instruments), from 70 to 145 1C, at a rate of 0.5 1C/min.
Test samples of weight 5 to 10 mg were weighed in crimped
aluminium sample pans.
2.3. Polymorph transformations
2.3.1. Effect of the crystallization solvents on the
crystalline forms
All crystallisations were obtained by dissolving the original
crystalline powder form (sample A: form II, sample B: form
III, sample C: form IIþIIIþmonohydrate) in different solvents
under constant stirring. Crystallization of each sample was
performed separately in isopropanol, hexaneþisopropanol
H. Bourichi et al.414(50:50, v/v), and methanolþwater (50:50, (v/v). The solutions
were ﬁltered into a warmed conical ﬂask through ﬁlter paper.
The evaporation of the ﬁltered solutions was performed under
different conditions (20 1C72 1C and RH% 5075; 20 1C7
2 1C and under vacuum), respectively during 72 h. The crystals
obtained was stored in amber glass bottles and kept in
desiccators over silica pellets at room temperature. Small
quantities were taken from each sample and analyzed with
time by FTIR and/or PXRD.2.3.2. Effect of temperature and or humidity on the
crystalline forms
Samples (A, B, C) were stored in the oven at 40 1C, 70 1C and
120 1C, respectively during one month. On the other hand, the
effect of the relative humidity on the stability of the crystals
was performed by storing the three samples at ambient
temperature but at different relative humidity (HR% 5075
and HR% more than 70%) during different times (t¼1; t¼2;
t¼7; t¼15days and 1; 2; and 3 months. Small quantities were
taken from each sample and analyzed with time by FTIR and/
or PXRD.5000
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2.4. Chromatographic analysis
HPLC analyses were performed on an Agilent series 1100
apparatus, equipped with an UV–visible diode array detector.
The detection was carried out at l¼261 nm, with 1 mL/min
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The column used to identifying and dosing ﬂuconazole is a
Nucleosil one (100C18, 125 mm 4 mm, 5 mm). The mobile
phase was composed of acetate buffer (pH 5.070.05; 0.01 M),
methanol and acetonitrile (v/v; 70: 20: 10).10
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2.4.2. Fluconazole impurities identiﬁcation and dosage
Impurity IMPI (i) dosage method (Method 1): the column used
is a Nucleosil one (100C18, 125 mm 4 mm, 5 mm).
The mobile phase is composed of a buffer of ammonium
dihydrogen phosphate and hexane sulphonic acid monohy-
drate salt, adjusted at pH 4.070.05 with phosphoric acid, and
acetonitrile (v/v; 85:15).
Impurities IMPII (h), IMPIII (a), IMPIV (g) and IMPV (f)
dosage method (Method 2): the column used is a Nova-Pack one
(100C18, 150 mm 3.9 mm, 4 mm). Separating these impurities
was carried out in a gradient mode, with a mixture of acetate
buffer at pH 5.070.05; acetonitrile and methanol as described in
Table 1.Table 1 Gradient for separating impurities: IPMII (h),
IMPIII (a), IMPIV (g) and IMPV (f).
Gradient Time
(min)
Acetonirile
(%)
Buffer
(%)
Methanol
(%)
Step0 10 5 80 15
Step1 20 55 30 15
Step2 3 55 30 15
Step2 2 5 80 153. Results and discussion
3.1. Loss on drying
The loss on drying results obtained for the three samples A, B,
and C are 0.46%, 0.31%, and 0.75%, respectively. The values
of sample A and B were less than the norm (0.5%) which is
recommended by the USP monograph on ﬂuconazole (USP
29), while the sample C had a volatile materials content that
was greater than required value (0.5%). The USP monograph
cited that ﬂuconazole must be stored in a sealed container at a
temperature under 30 1C.3.2. X-ray diffraction
Comparison of the diffractograms (Fig. 1A) showed that all
the samples generated characteristic diffraction lines between 5
and 351 (2y). The samples thus consisted in different poly-
morphs and/or phase mixtures. The diffraction lines of sample0
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Figure 1 A. X-ray diffractograms: (a) sample A, polymorph III;
(b) sample B, polymorph II; (c) sample C; (d) primary reference
standard; and (e) monohydrate. B. Calibration plot of the change
in integrated 101(2y) peak area as a function of polymorph II
concentration.
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while sample B matched polymorph II [11–15,17].
Neither the primary standard nor sample C matched any
previously described polymorph. The primary standard (d)
showed the coexistence of diffraction lines associated with
polymorphs II and III. In order to further elucidate the
composition of sample C, mixtures containing various
percentages of pure polymorphs II and III were prepared.
Quantitative determination was conducted on the integrated
intensity of the peak located at about 101(2y), which is speciﬁc
to form II [17]. Using the calibration plot of the change in the
integrated 101(2y) peak area as a function of polymorph II
concentration (Fig. 2B), the primary standard was found to
contain 80% of polymorph II and 20% of polymorph III. The
ﬁndings reported by Gu et al. also enabled XRD discrimina-
tion between crystalline polymorphs II and III [11]. In those
authors’’s study, determination was conducted on a mixture
containing 10% of polymorph II and 90% of polymorph III.200030004000
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Figure 2 FTIR spectra of the various samples: (a) sample A:
polymorph III; (b) sample B: polymorph II; (c) sample C; (d)
primary reference standard and (e) monohydrate. A represents the
frequency range: 4000–2000 cm1 and B represents range:
2000–400 cm1.Alkhamis et al. [13] have reported that polymorph II is a
metastable form that is converted to the more stable poly-
morph III. The diffractogram of the monohydrate form
prepared in the present study matched that reported in the
literature [12,15] but was not observed in any of the diffracto-
grams recorded on samples A and B. The monohydrate was
thus probably not present, only present at levels less than the
limit of detection, or present in an amorphous state.
The diffractogram recorded for sample C, is markedly
similar to that of the primary standard.
However, other lines present in the monohydrate diffracto-
gram were also present at: 8.1; 9.3; 12.77; 15.54 and 23.281 (2y)
(Fig. 1A). Moreover, the loss on drying results had demon-
strated that sample C had a volatile material content that was
greater than ﬁxed in the USP 29 monograph (0.75%).
Thus sample C consists in a mixture of forms II and III and
the monohydrate. Sample C thus probably consists in: either, partial conversions of polymorph II (metastable
form) to polymorph III (more stable form), which is
converted to the monohydrate under the inﬂuence of the
storage conditions, or a mixture of two batches of API from different
sources.Polymorph I, which can be obtained by synthesis [13] or
result from dehydration of the monohydrate [15], was not
detected in any of the samples.
3.3. Fourier-transform infrared spectroscopy
The samples were also examined using FTIR spectroscopy,
one of the methods most widely used to elucidate crystalline
polymorphism. As Fig. 2 shows, the spectra recorded on the
three samples (A, B and C) and the primary reference standard
exhibit noteworthy differences. Samples A and B clearly
consisted in polymorphs III and II [12–15,18].
Gu and Jiang have shown that Fourier-transform Raman
diffusion spectroscopy enabled complete characterization of a
mixture of ﬂuconazole polymorphs III and II [11]. The present
study evidenced these differences using transmission FTIR
spectroscopy.
The ﬂuconazole functional groups exhibit characteristic
bands. After the analysis and comparison of the FTIR spectra
recorded on the three samples, we reported in Table 2 a list of
the observed wave numbers, with the suggested assignments to
vibrations of the various functional groups present in the
molecule. The principal structural differences are attributed
to the vibrations associated with the triazole group, the
2,4-diﬂuorobenzyl group and the propane backbone.
With regard to the primary reference standard, the
frequency range from 4000 to 2000 cm1 is similar to those
of polymorphs II and III. The standard spectrum included the
bands at 3183, 3117, 3071, 3009 and 2968 cm1 that are
characteristic of polymorph III together with those between
2850 and 2600 cm1 characteristic of polymorph II. For the
frequency range between 2000 and 400 cm1, for each of the
bands located at 1274, 1210, 1139, 967, 849 and 677 cm1, a
contribution from at least two of the bands characteristic of
polymorphs II and III are observed. The bands at 1104 and
609 cm1 characteristic of polymorph III and those at 1116
and 616 cm1 in the spectrum of polymorph II are present.
Table 2 IR absorption bands characteristic of the groups present in the samples.
Assignment bands Form III (cm1) Form II (cm1) Monohydrate (cm1)
Residual water 3400 (sh) 3400 (br-m)
H-bonded OH str 3183 (br—m) 3185 (br-s)
Water 3156 (d-sharp-v-s)
CH str. Triazole ring 3117 (sharp-s) 3121 (sharp-m) 3116–3107 ((d-sharp-v-s)
CH str.Arom. ring 3071 (sharp-s) 3065 (br-m) 3063 (sharp-s)
CH str.Arom. ring 3009 (sharp-w) 3014 (sharp-m) 3020 (sharp-m)
CH2 str 2968 (sharp-w) 2794–2763–2738 triplets (sharp-w)
Overtones and combs1,2,4 1899–1844–1772 triplet
trisubst.Arom.ring (sharp-v-w) C¼C str.of 2,4
Diﬂuorobenzyl group 1620 (sharp-s) 1620 (sharp-m) 1620 (sharp-m)
1602 (w) 1600 (d-v-s) 1593–1506(d-sharp-v-s)
Triazole ring str./C¼C str
Arom ring 1506 (sharp-v-v)1518 (sh) 1516–1504 (d-v-s) 1516–1506 (d-sharp-v-s)
CH2 scissor of propane Backbone 1463 (sharp-w) 1465 (sharp-w) 1469 (sh)
CH2 scissor of propane
Backbone 1449 (w) 1453 (sharp-w) 1445 (sharp-w)
Triazole ring str 1420 (sharp-m) 1413 (sharp-m) 1407 (sh) 1422 (sharp-s)
C¼C str.Arom.ring/ ring str. 1387 (sharp-m) 1371 (sharp-w)
of triazole group 1367 (v-w) 1353 (v-w) 1360 (sharp-w)
CH bend of propane backbone 353 (sh)
C¼C str. Arom. Ring 343 (sharp-w) 1345 (sharp-v-w) 1349 (w)
Triazole ring str 1317 (v-w) 1317 (w) 1304 (sharp-w)
1294 (w) 1300 (sharp-w) 1281 (sh)
OH def./CF str. of 2, 4 1278 (sharp-v-s) 1272 (sharp-v-s) 1276 (sharp-s)
diﬂuorobenzyl group
b-CH Arom. ring/ring str 1260 (sharp-w) 1254 (sharp-w) 1249 (sharp-w)
of triazole group
b-CH triazole ring 1220–1211 (d-m) 1210 (sharp-m) 1220 (sh) 1227–1218–1210 Triplet (w)
1160 (sharp-v-w) 1162 (sharp-w) 1202 (sh)
Ring breathing of triazole
Group 1144 (sharp-v-s) 1138 (sharp-v-s) 1140 (sharp-v-s)
CF str./C-C str. of propane 1104 (sharp-s) 1116 (sharp-s) 112 (sharp-m)
backbone
C–OH str./CH def. of 2, 4 1084–1078 (d-s) 1090 (sharp-w) 1075 (sharp-m) 1083 (sharp-m)
diﬂuorobenzyl group 1046 (sharp-v-w) 1050 (sharp-v-w) 1040
(sharp-v-w)
b-CH Arom. ring/C-(OH) str. 1017 (sharp-m) 1026–1011 (d-sharp-w) 1019 (sharp-m)
of propane backbone
Oˆ-CH triazole ring/ring bend of 966 (sharp-s) 968–960 (d-m) 968 (sharp-v-s)
triazole group
Triazole ring def 909 (sharp-w) 910 (sharp-w) 917 (sharp-m) 942 (sharp-v-w)
896 (w) 898 (sharp-w)
g-CH Arom. Ring 885 (sharp-m) 888 (sharp-w) 870 (sharp-w)
g-CH triazole ring 850 (sharp-v-s) 846 (sharp-s) 853 (sharp-m) 834 (sharp-m)
g-CH Arom ring 818–794 (d-sharp-w) 820 (sh) 810–803 (d-w) 813–801–790–780 (v-w) 767
(sharp-w) 761 (sh)
g-CH triazole ring CH2 rock 760–738 (d-sharp-w) 791 (w) 768 (sharp-w) 733 (sharp-w) 747 (v-w) 736 (sharp-w) 726 (sh )
g-CH Arom. Ring 702 (sh) 711 (sharp-w) 715 (sharp-v-w)
Arom ring def. 681 (sharp-m) 692 (sh) 674 (sharp-m) 696 (sharp-w) 680 (sharp-m)
Triazole ring def 658 (sharp-m) 648 (sh) 651 (sharp-m) 653 (sharp-m)
Arom. ring def 609 (sharp-w) 616 (sharp-w) 605 (sh) 617 (w) 607 (sh)
Sh shoulder. s : strong. m : medium. w : weak. v : very. br : broad. d: doublet.
H. Bourichi et al.416The monohydrate is indeed present in the spectrum of the
primary standard as shown by the bands at 3155 and
834 cm1. The same remarks can also be formulated for
sample C. However, the intensities of the shoulders and bands
of the monohydrate form are more marked (Fig. 2A and B).
The broad band centered at 3400 cm1 and generated
by the residual water content is more intense forsample C, conﬁrming the results of the loss on drying study
(Section 3.1).
3.4. Differential scanning calorimetry
The DSC thermograms of samples A, B and C are shown in
Fig. 3. For sample A, a single endothermal peak is observed
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Figure 3 DSC thermograms of the samples: (a) sample A:
polymorph III; (b) sample B: polymorph II and (c) sample C.
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The melting point of sample B was 138.6 1C indicating the
presence of polymorph II [12–14]. The ﬁndings conﬁrm the
XRD and vibrational spectroscopy results and are concordant
with the published data.
However, the sample C thermogram showed the principal
endothermal peak of form III at 139.2 1C, with a very
pronounced shoulder at about 138.4 1C, indicating the pre-
sence of polymorph II. During heating, a quantity of the
metastable ﬂuconazole polymorph II was probably converted
to the more stable form III.
In addition, an endothermal peak is present at about
101.7 1C, reﬂecting dehydration of the monohydrate fraction
[9]. The thermal proﬁle of sample C further conﬁrms the XRD
and FTIR spectroscopic results.3.5. Effect of solvent on the crystalline forms
Crystallization is an operation of puriﬁcation and crystal
formation. The nature of the solvent used is among the gotten
essential factors responsible for the ﬁnal crystalline shape
[19–21].
The results of the identiﬁcation of the different crystalline
powders (A, B, C) after their re-crystallization in different
solvents followed by evaporation at 20 1C72 1C and RH%
5075, showed that the three samples were transformed into
the monohydrate forms. The form II is found once we realized
the crystallization at a temperature of 2072 1C but under
vacuum. These solvents were selected because there were the
solvents used in preparation of the APIs as solvents of
puriﬁcation.
However, desolvation, under vacuum at a temperature of
60 1C for 3 h, of the monohydrate form obtained from the
form II and form III has allowed us to obtain form III.
During our experiments with different APIs of ﬂuconazole,
we found the appearance of the monohydrate in the various
samples. This prompted us to conduct a study of stable
ﬂuconazole polymorphic forms depending on the temperature
and humidity in aim to determine the conditions of conserva-
tion of the APIs.
It should be noted that the monograph of European
Pharmacopoeia described ﬂuconazole as a hygroscopicpowder [22] and the American Pharmacopeia [23] it is
mentioned that we must keep this API in brown tight
containers at a temperature below 30 1C.3.6. Effect of temperature on crystalline transformation
In order to evaluate thermal transformation, we kept samples:
pure form II, pure form III and mixture of forms in oven set at
40 1C, 70 1C and 120 1C during a month. The identiﬁcation
by FT-IR spectroscopy were performed on Small quantities
of each sample after 1 days, 2 days, 3 days, 4 days, 5 days, 6 days,
7 days, 15 days, 20 days, 25 days and last 30 day.
We noted no phase transformation in form II or form III.
However, in the literature [14], we found that form II is a
metastable form of ﬂuconazole, which is spontaneously
transformed into form III at room temperature and under
pressure. Indeed, according to this study, the total transforma-
tion of form II to III is produced in a period less than a
month. The form II that the authors used to demonstrate this
transformation was prepared by crystallization of form III in
methanol. We have therefore prepared the form II as shown in
this study and we have kept it under the same conditions
mentioned. No transformation was observed.
On the sample C, after one day we noticed the disappear-
ance of the monohydrate form. This disappearance has
been rated for temperatures 40 1C, 70 1C and 120 1C. Indeed,
the FTIR spectra recorded showed the coexistence of the
single form II and III. Probably, this was the desolvation of
the monohydrate form giving rise to the form III (as pre-
show).3.7. Effect of relative humidity on crystalline transformation
This study was conducted according to the relative humidity,
into two distinct conditions: RH¼50% (75) and RHZ70%
as was described in Section 2.3.2.
If we consider sample A (form II), we noted the appearance
of form II on its FT-IR spectrum after the ﬁrst day. Probably,
part of the form III was transformed into form II under the
inﬂuence of relative humidity. To our knowledge, this trans-
formation has never been demonstrated in the references
dealing with polymorphic transformations of ﬂuconazole.
Consequently, we deemed appropriate to analyze this sample
PXRD. Indeed, we noted on the XR diffractogram character-
istic peak of form II located about 21(2y).
Regarding the two samples corresponding to form II as
obtained from the supplier and that obtained by crystal-
lization of form III into methanol, we have noted that they
have the same behavior according to the ambient humidity.
Indeed, we noted the formation of the monohydrate form on
the 2nd day and then no transformation has been noted for
3 months under the same conditions.
On the sample C (form IIþIIIþmonohydrate), we noted no
polymorphic transformation at 5075% (RH) but at (RH)
more than 70% it was a total transformation to the mono-
hydrate form.
If we consider the samples kept at ambient temperature and
humidity (more than 70%), we noted the same observations as
humidity set at 5075% (RH), except that all samples were
transformed to monohydrate form after 3 months.
H. Bourichi et al.418According to the results obtained by the study of stability
depending on the temperature and humidity, we can conclude that:T
aCrystalline forms II and III of ﬂuconazole were not
affected by temperature even at high ones which is in
contradiction with references [14]. The ﬂuconazole APIs are very sensitive to moisture and
at relative humidity of 5075%, we have a transformation
of forms III and II in monohydrate form.able 3 Fluconazole impurities.
Origin Impurities
synthesis Impurity Impurity III (a)
2-(2,4-diﬂuorophe´nyl)-1-(1H-1-,2,4-triazol-1-yl)-3-(
propanol ‘‘me´lange race´mique’’
Impurity b
2-[2-ﬂuoro-4-(1H-1,2,4-triazol-1-yl)-1,3-bis(1H-1,2,
Impurity c
1,10-(1,3-phenylene) di (1H-1,2,4-triazole)
Impurity d
2-(4-ﬂuorophe´nyl)-1,3-bis(1H-1,2,4-triazol-1-yl)pro
Degradation or
synthesis
product
Impurity e
1-[(6RS)-4,6-diﬂuoro-6-(1H-1,2,4-triazol-1yl)cycloh
die´nyl]e´thanone
Impurity V (f)
2-(2,4-diﬂuorophe´nyl)-2,3-dihydroxypropyl-1H-1,2
Degradation
product
Impurity IV (g)
2-(2,4-diﬂuorophe´nyl)-2,3-epoxypropyl-1H-1,2,4-tr
Synthesis
impurity
Impurity II (h)
2-(2,4-diﬂuorophenyl)-1-bromo-3-(1H-1,2,4-triazol
‘‘ﬂuconazole bromohydrure’’
Impurity I (i)
2-(2,4-diﬂuorophe´nyl)-1-(1H-1-,2,4-triazol-1-yl)-3-(
triazonio-1-yl)-2-propanol, bromure ‘‘ﬂuconazole
Impurity j [24]
Z-2-(2,4-diﬂuorophenyl)-3-(1-H-1,2,4-triazole-1-yl)
Impurity k [24]
2-(2-(dimethylamino)-4-ﬂuorophenyl)-1,3-di(3H-1,2,4
, b, c, d, e, f, g, h and i: impurities cited in European pharmacopoeia [23.8. Chromatographic analysis
Before to start the impurities analysis, we have gathered
in Table 3, the impurities described by the three API
manufacturers (A, B, C) as well as those from the European
and US Pharmacopoeias [22,23]. This table equally reports the
different impurities structures, their origins, their limit levels
as well as their dosage methods. Signiﬁcant differences appear
between manufacturers, whether at the searched impuritiesStructures Methods
CCM
4H-1,2,4-triazol-4-yl)-2- HPLC
CCM
4-triazol-1-yl)-2-propanol HPLC
CCM
HPLC
pan-2-ol
exa-1,4-
,4-triazole
iazole
-1-yl)-2-propanol
4H-4-amino-1,2,4-
quaternaire’’
-2-propen-1-ol
-triazol-1-yl)propan-2-ol
2];.b, c and d: impurities cited in American pharmacopoeia [23].
Table 4 Fluconazole organic impurities dosage results.
Samples and
re-crystallisation
solvent
Method 1 Method 2
P
Impurities
IMP I (i)
(4.65 min)
Impurities non
identiﬁed
IMPII (h)
(23.6 min)
IMPIII (a)
(4.1 min)
IMPIV (g)
(18.6 min)
IMPV (f)
(6.7 min)
Sample A 0.38 % 0.01% ND 0.34 % ND ND 0.76 %
Isopropanol 0.03 %
Sample B 0.03 % 0.01 % ND ND ND 0.08 % 0.26 %
Isopropanol 0.04 %
and Hexane 0.08 %
0.02 %
Sample C 0.35 % 0.03 % ND 0.38 % ND 0.08 % 1.07 %
Me´thanol 0.15 %
and Eau 0.04 %
0.02 %
0.02 %
0
0
1
2
3
0
0
1
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1
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Figure 4 HPLC Chromatograms of ﬂuconazole samples with the IMPI dosage method.
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H. Bourichi et al.420number and nature level, or at the recommended dosage
method level. Considering only the three samples belonging
to our three suppliers, we observed that the presence of
three synthesis impurities (a, b and c) was reported by the
manufacturer A, with thin-layer chromatography (TLC)
as control method. The same impurities were quantiﬁed
through HPLC by the manufacturer B. Conversely, the
manufacturer C describes only two impurities (a and b)
with HPLC as dosage method. The ﬂuconazole European
Pharmacopoeia monograph speciﬁes the impurities a, b and c
while the US monograph only describes the three impurities b,
c and d.
The impurities [IMPI (i), IMPII (h), IMPIII (a), IMPIV (g) and
IMPV (f)] coming either from synthesis or degradation and which
are mentioned in the European Pharmacopoeia monograph, but
are not searched by the three manufacturers, except IMPIII (a).0
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Figure 5 HPLC Chromatograms of Fluconazole samples withThe results achieved with both dosage methods showed that
impurities levels are widely lower than the speciﬁcations set,
whatever the API origin (Table 4).
In addition, the IMPI dosage method allowed us to drawing
the following observations: (m
 (
 (m
0
0
0
Iin)
min
in)
PMIMPI (TR¼4.65 min) is present in the three APIs, at
different levels. Actually, as showed in Fig. 4, both
samples A and C contain this impurity at a similar level
of approximately 0.35%, while sample B contains this
impurity in a very low quantity (0.03%); Sample A chromatogram contains, in addition to
IMPI, two other wide, small surfaced peaks, respectively
located at 11.2 and 13.8 min. Both peaks may be due to
the a, b or c impurities, since Pﬁzer, the discovering
laboratory, only speciﬁes three impurities, a, b and c;)
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II; IMPIII; IMPIV and IMPV dosage related method.
Solid-state characterization and impurities determination of ﬂuconazol generic products marketed in Morocco 421 In addition, we noted, on samples B and C, the appear-
ance of other small surfaced peaks due to unidentiﬁed
impurities.If we consider now the second IPMII; IMPIII; IMPIV and
IMPV dosage related method, we note that only IMP III is
present on sample A, while B solely contains IMPV. Sample C
contains both impurities (Table 4).
While examining the results (Fig. 5), we noted that,
actually, the sample C related chromatogram is the addition
of those related to samples A and B. The same observations
were reported, basing on the IMP II, IMP III, IMP IV and
IMP V dosage method (Table 4).
Let us remind that sample A is solely composed of the
crystalline form III and sample B contains the pure crystalline
form II, while C is a mixture of three polymorphic forms: III,
II and the monohydrate form.
We also noted differences at APIs manufacturing plans
level, in particular at the end puriﬁcation solvents level, which
explains on the one hand, the difference between polymorphic
forms and, on the other hand, the difference between the
corresponding impurities.
Given the results achieved above, concerning every raw
material, the relationship between the different crystalline
forms of ﬂuconazole and the possible presence of impurities
speciﬁc to every polymorph is clearly obvious. It is, therefore,
possible, from the impurities determination related chromato-
grams, to get previous information on the polymorph(s) in
which presents the API in question.4. Conclusion
We noted remarkable differences on the physical and chemical
purity of the different APIs. Indeed, physicochemical char-
acterization by XRD, FTIR spectroscopy and DSC enabled
differentiation of the three APIs samples. Sample A entirely
consisted of polymorph III, sample B entirely consisted of
polymorph II, and sample C consisted in a mixture of
polymorphs II and III and the monohydrate.
A relationship between ﬂuconazole speciﬁc impurities and
crystalline form was clariﬁed by using HPLC. It is therefore
possible, from the impurities dosage results achieved through
HPLC, to distinguish the different ﬂuconazole crystalline
polymorphs.
It was interesting to investigate the factors affecting ﬂuco-
nazole polymorphic transformations. In fact, relative humidity
proved to transform both polymorphs to monohydrate form.
While, no transformations were noted due to the high
temperatures, both form II and III showed high stability in
high isothermal.
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